FindTrial
Sign In

ADCETRIS 50 mg powder for concentrate for solution for infusion.

DRUG3 trials

Sponsors

University Of Cologne, Universita' Degli Studi Di Perugia, Assistance Publique Hopitaux De Paris

Conditions

Advanced Stage of Classic Hodgkin LymphomaPatients with relapsed or refractory cHL that has not responded toor has progressed afterrare diseasethe previous treatment. Neither Cohort-1 nor Cohort-2 are open to patients with a partial response after the immediate prior treatment (including salvage therapy before autologous or allogeneic transplantation); such patients would become eligible only upon subsequent progression.

Phase 2

A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL)
RecruitingCTIS2024-520123-83-01
Universita' Degli Studi Di Perugiaor has progressed after, Patients with relapsed or refractory cHL that has not responded to, the previous treatment. Neither Cohort-1 nor Cohort-2 are open to patients with a partial response after the immediate prior treatment (including salvage therapy before autologous or allogeneic transplantation); such patients would become eligible only upon subsequent progression.
Start: 2020-02-11Target: 48Updated: 2026-01-23
Pembro-FLASH - Phase II trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classic Hodgkin Lymphoma
Not yet recruitingCTIS2022-501458-13-01
University Of CologneAdvanced Stage of Classic Hodgkin Lymphoma
Target: 40Updated: 2025-09-30

Phase 3

BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance
Not yet recruitingCTIS2025-521093-34-00
Assistance Publique Hopitaux De Parisrare disease
Target: 84Updated: 2026-01-15